Epistem Holdings Plc (LSE: EHP), the personalised medicine and biotechnology company, is pleased to announce that, following his appointment as Chief Executive Officer and as Board Director as announced on 13 January 2016, David Budd will join Epistem on 1 March 2016.
David has over 20 years of international commercial and operational experience in the diagnostics and medical devices field, launching multiple diagnostics products into international markets. He joins from Leica Biosystems (a Danaher company), a fast growing organisation where he served as General Manager of Leica Biosystems Amsterdam. David previously served as Commercial Director at Leica Biosystems Newcastle, with global responsibility for marketing, market research and product launches for diagnostic tests.
Prior to joining Leica Biosystems, David's previous roles included Point-of-Care, molecular, and central laboratory marketing and commercialization responsibilities as a Director of Marketing at Siemens Healthcare Diagnostics, Business Unit Leader at Bayer Diagnostics UK, and Sales Manager at Visible Genetics Inc.
- Ends –
For further details please contact:
Epistem Holdings Plc
Dr Ian Gilham: Chairman +44 (0)161 606 7258
John Rylands: Finance Director
Peel Hunt LLP
James Steel +44 (0)207 418 8900
Tom Burt
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Laura Thornton
[email protected]
Notes to Editors
Epistem is a personalised medicine and biotechnology company developing innovative diagnostics and biomarkers alongside providing contract research services to drug development companies. Epistem's Genedrive® is a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test is now being prepared for launch in India and the Indian sub-continent. Further details can be found at: www.epistem.co.uk and www.genedrive.com